Guarino Salvatore, Giusti Deborah Maria, Rubini Antonello, Favoriti Pasqualino, Fioravanti Cristina, Di Matteo Filippo Maria, D'Andrea Vito, De Antoni Enrico, Catania Antonio
Department of Surgical Sciences, "Sapienza" University of Rome, Rome, Italy.
Department of Radiology, Oncology and Anatomy Pathology, "Sapienza" University of Rome, Rome, Italy.
Clin Med Insights Case Rep. 2013 Dec 9;6:197-200. doi: 10.4137/CCRep.S13021. eCollection 2013.
Here we report a case of panhypopituitarism caused by pituitary Langerhans cell hystocitosis (LCH) in a 22-year-old woman affected by papillary thyroid carcinoma (PTC). Although several cases of the coexistence of PTC and LCH within thyroid tissue have been described in relative literature, in this case, the patient presented a unique suprasellar retrochiasmatic histocytosis localization which, to the best of our knowledge, had never been described before in association with PTC. Even if this aspect is not addressed in the present case report, it is worth noting that about 50% of the patients affected either by LCH or PTC are characterized by activating mutations of the proto-oncogene BRAF. This, along with other clinical studies, may warrant further biomolecular large-scale case study investigations in order to evaluate a possible connection between the 2 conditions and shed light on the etiology of these diseases, which are still largely unknown.
在此,我们报告一例22岁患有乳头状甲状腺癌(PTC)的女性因垂体朗格汉斯细胞组织细胞增多症(LCH)导致全垂体功能减退的病例。尽管相关文献中已描述了甲状腺组织内PTC与LCH共存的几例病例,但在本病例中,患者出现了一种独特的鞍上视交叉后组织细胞增多症定位,据我们所知,此前从未有过与PTC相关的描述。即使本病例报告未涉及这一方面,但值得注意的是,约50%受LCH或PTC影响的患者具有原癌基因BRAF的激活突变。这一点以及其他临床研究可能需要进一步开展大规模生物分子病例研究,以评估这两种病症之间可能存在的联系,并阐明这些疾病在很大程度上仍未知的病因。